JP2002371013A - 抗ｃｔｌａ−４抗体の使用 - Google Patents

抗ｃｔｌａ−４抗体の使用

Info

Publication number
JP2002371013A
JP2002371013A JP2002142978A JP2002142978A JP2002371013A JP 2002371013 A JP2002371013 A JP 2002371013A JP 2002142978 A JP2002142978 A JP 2002142978A JP 2002142978 A JP2002142978 A JP 2002142978A JP 2002371013 A JP2002371013 A JP 2002371013A
Authority
JP
Japan
Prior art keywords
ser
cancer
val
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002142978A
Other languages
English (en)
Japanese (ja)
Inventor
Douglas Charles Hanson
チャールズ ハンソン ダグラス
Eileen Elliott Mueller
エリオット ムエラー エイリーン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of JP2002371013A publication Critical patent/JP2002371013A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002142978A 2001-05-23 2002-05-17 抗ｃｔｌａ−４抗体の使用 Pending JP2002371013A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23
US60/293042 2001-05-23

Publications (1)

Publication Number Publication Date
JP2002371013A true JP2002371013A (ja) 2002-12-26

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002142978A Pending JP2002371013A (ja) 2001-05-23 2002-05-17 抗ｃｔｌａ−４抗体の使用

Country Status (14)

Country Link
US (1) US20030086930A1 (cg-RX-API-DMAC10.html)
EP (1) EP1262193A1 (cg-RX-API-DMAC10.html)
JP (1) JP2002371013A (cg-RX-API-DMAC10.html)
KR (1) KR100531707B1 (cg-RX-API-DMAC10.html)
CN (1) CN1404876A (cg-RX-API-DMAC10.html)
AU (1) AU4242102A (cg-RX-API-DMAC10.html)
CA (1) CA2382443A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ20021760A3 (cg-RX-API-DMAC10.html)
HU (1) HUP0201737A2 (cg-RX-API-DMAC10.html)
IL (1) IL149701A0 (cg-RX-API-DMAC10.html)
MY (1) MY136095A (cg-RX-API-DMAC10.html)
PL (1) PL354112A1 (cg-RX-API-DMAC10.html)
SK (1) SK7242002A3 (cg-RX-API-DMAC10.html)
ZA (1) ZA200204020B (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502330A (ja) 2003-05-30 2007-02-08 メダレックス インコーポレイテッド 抗ｃｔｌａ−４に基盤を置く病気の免疫療法の代用治療終末点
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
JP2009500412A (ja) * 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
JP2014077015A (ja) * 2005-05-09 2014-05-01 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
CN112218892A (zh) * 2018-03-19 2021-01-12 上海药明生物技术有限公司 新型抗ctla-4抗体多肽

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN1652820A (zh) * 2002-04-12 2005-08-10 梅达雷克斯公司 使用ctla－4抗体的治疗方法
PL377091A1 (pl) 2002-09-06 2006-01-23 Amgen, Inc. Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
EP2457587A1 (en) 2003-06-27 2012-05-30 Amgen Fremont Inc. Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
KR101215218B1 (ko) 2003-07-22 2012-12-26 바이엘 파마 악티엔게젤샤프트 Ｒｇ１ 항체 및 그의 용도
EP1660537A2 (en) 2003-08-14 2006-05-31 Dyax Corp. Endotheliase-2 ligands
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
AU2005225227A1 (en) * 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-CTLA-4 antibodies
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
KR20070067702A (ko) * 2004-11-04 2007-06-28 화이자 프로덕츠 인크. 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
PT2620450T (pt) 2005-03-08 2018-12-17 Pfizer Prod Inc Composições de anticorpos anti-ctla-4
BRPI0609427A2 (pt) * 2005-03-23 2010-04-06 Pfizer Prod Inc composição farmacêutica para o tratamento de cáncer de próstata e uso de um agente de terapia hormonal e de um anticorpo, ou uma porção de ligação a antìgeno do mesmo
CA2602316A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Institute métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
JP2009518446A (ja) 2005-12-07 2009-05-07 メダレックス インコーポレーティッド Ｃｔｌａ−４抗体投与量漸増レジメン
CA2647282A1 (en) * 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
WO2009016449A1 (en) * 2007-07-27 2009-02-05 Pfizer Limited Antibody purification process by precipitation
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
US8449886B2 (en) 2008-01-08 2013-05-28 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
MX2012000851A (es) * 2009-07-20 2012-06-08 Squibb Bristol Myers Co Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
TR201905909T4 (tr) 2011-04-19 2019-05-21 Pfizer Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
MX365139B (es) 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
MX364265B (es) * 2012-08-23 2019-04-17 Agensys Inc Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7.
JP2016500251A (ja) * 2012-12-03 2016-01-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 免疫調節Ｆｃ融合タンパク質の抗癌活性の増強
BR112016002614B8 (pt) 2013-08-08 2023-11-07 Hopitaux Paris Assist Publique Imunocitoquina e composição farmacêutica
KR102457731B1 (ko) 2013-08-08 2022-10-21 싸이튠 파마 병용 약학 조성물
MX377714B (es) * 2013-10-18 2025-03-11 Regeneron Pharma Composiciones que comprenden una combinación de un antagonista de vegf y un anticuerpo anti-ctla-a.
JP6712952B2 (ja) * 2014-03-31 2020-06-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 固形腫瘍悪性病変を処置するための、抗ｃｔｌａ−４抗体および／または抗ｐｄ−１抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
SG10201809450VA (en) * 2014-05-01 2018-11-29 Anaeropharma Science Inc Heterogeneous polypeptide expression cassette
CA2949998A1 (en) 2014-05-28 2015-12-03 Agenus Inc. Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
HRP20190881T1 (hr) 2014-08-28 2019-07-12 Halozyme, Inc. Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
AU2015328411C1 (en) 2014-10-06 2022-03-03 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
CA3203273A1 (en) 2014-10-14 2016-04-21 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
JP6885867B2 (ja) 2014-12-31 2021-06-16 チェックメイト ファーマシューティカルズ， インコーポレイテッド 組合せ腫瘍免疫療法
AR103675A1 (es) * 2015-02-13 2017-05-24 Sorrento Therapeutics Inc Anticuerpos anti-ctla4 terapéuticos
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
WO2017015560A2 (en) * 2015-07-22 2017-01-26 Sorrento Therapeutics, Inc. Antibody therapeutics that bind lag3
EP3337495A4 (en) * 2015-08-18 2019-04-10 Mateon Therapeutics, Inc. USE OF VDA TO ENHANCE IMMUNOMODULATION THERAPIES AGAINST TUMORS
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
TW201735949A (zh) 2016-03-24 2017-10-16 千禧製藥公司 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法
US20190046638A1 (en) 2016-04-01 2019-02-14 Checkmate Pharmaceuticals, Inc. Fc RECEPTOR-MEDIATED DRUG DELIVERY
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
PT3551660T (pt) * 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
CA3089768A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Mutant anti-ctla-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
CN112236522A (zh) 2018-04-09 2021-01-15 查克美特制药公司 寡核苷酸包装到病毒样颗粒中
KR102869944B1 (ko) 2018-07-11 2025-10-15 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
WO2021238932A1 (zh) * 2020-05-26 2021-12-02 百奥泰生物制药股份有限公司 多特异性抗体及其应用
JP7758369B2 (ja) 2020-07-10 2025-10-22 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｇａｓ４１阻害剤及びその使用方法
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
PL210435B1 (pl) * 1998-12-23 2012-01-31 Amgen Fremont Inc Ludzkie przeciwciała monoklonalne wiążące się z CTLA-4
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
KR20020047132A (ko) * 1999-08-24 2002-06-21 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007502330A (ja) 2003-05-30 2007-02-08 メダレックス インコーポレイテッド 抗ｃｔｌａ−４に基盤を置く病気の免疫療法の代用治療終末点
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
JP2014077015A (ja) * 2005-05-09 2014-05-01 Ono Pharmaceut Co Ltd ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
JP2009500412A (ja) * 2005-07-07 2009-01-08 コーリー ファーマシューティカル グループ，インコーポレイテッド 癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
CN112218892A (zh) * 2018-03-19 2021-01-12 上海药明生物技术有限公司 新型抗ctla-4抗体多肽

Also Published As

Publication number Publication date
US20030086930A1 (en) 2003-05-08
CZ20021760A3 (cs) 2003-05-14
IL149701A0 (en) 2002-11-10
CA2382443A1 (en) 2002-11-23
ZA200204020B (en) 2003-11-21
PL354112A1 (en) 2002-12-02
HUP0201737A2 (hu) 2003-02-28
AU4242102A (en) 2002-11-28
HU0201737D0 (cg-RX-API-DMAC10.html) 2002-07-29
SK7242002A3 (en) 2003-07-01
CN1404876A (zh) 2003-03-26
MY136095A (en) 2008-08-29
KR20020090873A (ko) 2002-12-05
KR100531707B1 (ko) 2005-11-30
EP1262193A1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
KR100531707B1 (ko) 항-ｃｔｌａ-4 항체의 용도
TW200829271A (en) Uses of anti-CTLA-4 antibodies
KR102806206B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
US6682736B1 (en) Human monoclonal antibodies to CTLA-4
CN1328571B (zh) 抗ctla-4的人单克隆抗体
KR101262032B1 (ko) ＭＡｄＣＡＭ에 대한 항체
US20040228861A1 (en) Human monoclonal antibodies to CTLA-4
KR20070104673A (ko) 암의 치료를 위한 항－ｃｔｌａ４ 항체와 인돌리논병용요법
KR20070067702A (ko) 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법
KR20050059263A (ko) 에리트로포이에틴 수용체 결합 항체
CN101027322A (zh) 促红细胞生成素受体结合抗体
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
KR20070108259A (ko) Ｃｔｌａ-4 항체와 호르몬 요법에 의한 전립선암의 치료법
HK1103020A (en) Uses of anti-ctla-4 antibodies
HK1050849A (en) Use of anti-ctla-4 antibodies
HK1115297A (en) Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060703

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060706

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20061212